Author

B. Weissman

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 2 Approach:experimental assay· 2 Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell type annotation· 1 Research Focus:cell-cell communication· 1 Organism:human· 1 Organism:mouse· 1

Frequent Co-Authors

A. Weston· 1 shared B. Bowman· 1 shared C. Huang· 1 shared C. Paiboonrungruang· 1 shared D. Lamson· 1 shared E. W. Livingston· 1 shared H. Vankayalapati· 1 shared H. Yuan· 1 shared

Activity by Year

2020-2023 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 24 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

A. Weston

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Small Molecule Screen Identifies Pyrimethamine as an Inhibitor of NRF2-driven Esophageal Hyperplasia

C. Paiboonrungruang, Z. Xiong, D. Lamson, Y. Li, B. Bowman, J. Chembo, C. Huang, J. Li, E. W. Livingston, J. E. Frank, V. Chen, Y. Li, B. Weissman, H. Yuan, K. P. Williams, , X. Chen

This study identifies pyrimethamine as an NRF2 inhibitor that suppresses esophageal hyperplasia in a mouse model and shows potential for clinical use in NRF2-high ESCC.

Redox Biology · Nov 1, 2023Peer-reviewedCancer Biology

The novel reversible LSD1 inhibitor SP-2577 promotes anti-tumor immunity in SWItch/Sucrose-NonFermentable (SWI/SNF) complex mutated ovarian cancer

R. Soldi, T. Ghosh Halder, A. Weston, T. Thode, K. Drenner, R. Lewis, M. R. Kaadige, S. Srivastava, S. Daniel Ampanattu, R. Rodriguez del Villar, J. D. Lang, H. Vankayalapati, B. Weissman, J. Trent, W. Hendricks, S. Sharma

This study shows that the LSD1 inhibitor SP-2577 enhances anti-tumor immunity and PD-L1 expression in SWI/SNF-mutated ovarian cancer models.

bioRxiv · Jan 10, 2020Cancer Biology